Pranav Garimella

Dr. Pranav Garimella


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2013 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
HFHoward A. Fink
Howard A. Fink
TWTimothy J. Wilt
Timothy J. Wilt
KEKeith E. Eidman
Keith E. Eidman
PGPranav Garimella
Pranav Garimella
RMRoderick MacDonald
Roderick MacDonald
MMManoj Monga
Manoj Monga
This article has been corrected. The original version (PDF) is appended to this article as a supplement. Background: Optimum management to prevent recurrent kidney stones is uncertain. Purpose: To evaluate the benefits and harms of interventions to prevent recurrent kidney stones. Data Sources: MEDLINE, Cochrane, and other databases through September 2012 and reference lists of systematic reviews and randomized, controlled trials (RCTs). Study Selection: 28 English-language RCTs that studied treatments to prevent recurrent kidney stones and reported stone outcomes. Data Extraction: One reviewer extracted data, a second checked accuracy, and 2 independently rated quality and graded strength of evidence. Data Synthesis: In patients with 1 past calcium stone, low-strength evidence showed that increased fluid intake halved recurrent composite stone risk compared with no treatment (relative risk [RR], 0.45 [95% CI, 0.24 to 0.84]). Low-strength evidence showed that reducing soft-drink consumption decreased recurrent symptomatic stone risk (RR, 0.83 [CI, 0.71 to 0.98]). In patients with multiple past calcium stones, most of whom were receiving increased fluid intake, moderate-strength evidence showed that thiazides (RR, 0.52 [CI, 0.39 to 0.69]), citrates (RR, 0.25 [CI, 0.14 to 0.44]), and allopurinol (RR, 0.59 [CI, 0.42 to 0.84]) each further reduced composite stone recurrence risk compared with placebo or control, although the benefit from allopurinol seemed limited to patients with baseline hyperuricemia or hyperuricosuria. Other baseline biochemistry measures did not allow prediction of treatment efficacy. Low-strength evidence showed that neither citrate nor allopurinol combined with thiazide was superior to thiazide alone. There were few withdrawals among patients with increased fluid intake, many among those with other dietary interventions and more among those who received thiazide and citrate than among control patients. Reporting of adverse events was poor. Limitations: Most trial participants had idiopathic calcium stones. Nearly all studies reported a composite (including asymptomatic) stone recurrence outcome. Conclusion: In patients with 1 past calcium stone, increased fluid intake reduced recurrence risk. In patients with multiple past calcium stones, addition of thiazide, citrate, or allopurinol further reduced risk. Primary Funding Source: Agency for Healthcare Research and Quality.

1 July 2009 in European Urology
Verified
Journal Article
Closed access
HFHoward A. Fink
Howard A. Fink
JAJoseph W. Akornor
Joseph W. Akornor
PGPranav Garimella
Pranav Garimella
RMRod MacDonald
Rod MacDonald
ACAndrea Cutting
Andrea Cutting
TWTimothy J. Wilt
Timothy J. Wilt

1 August 2019 in Cardiology Clinics
Verified
Journal Article
Closed access
UKUjjala Kumar
Ujjala Kumar
NWNicholas Wettersten
Nicholas Wettersten
PGPranav Garimella
Pranav Garimella

1 November 2014 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
PGPranav Garimella
Pranav Garimella
AHAlan T. Hirsch
Alan T. Hirsch

1 October 2012 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
PGPranav Garimella
Pranav Garimella
PHPeter D. Hart
Peter D. Hart
AOAnn O'HAre
Ann O'HAre
SDStephanie DeLoach
Stephanie DeLoach
CHCharles A. Herzog
Charles A. Herzog
AHAlan T. Hirsch
Alan T. Hirsch

2 October 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KLKaice LaFavers
Kaice LaFavers
EMEtienne Macedo
Etienne Macedo
PGPranav Garimella
Pranav Garimella
CLCamila de Enfermagem de Ribeirão Preto da Universidade de São Lima
Camila de Enfermagem de Ribeirão Preto da Universidade de São Lima
SKShehnaz Khan
Shehnaz Khan
RMRadmila Micanovic
Radmila Micanovic
Uromodulin inhibits systemic oxidative stress via TRPM2.